References
Sebastianelli A, Gacci M. Current status of the relationship between metabolic syndrome and lower urinary tract symptoms. Eur Urol Focus. 2018;4:25–7.
Gacci M, Sebastianelli A, Salvi M, De Nunzio C, Vignozzi L, Corona G, et al. Benign prostatic enlargement can be influenced by metabolic profile: results of a multicenter prospective study. BMC Urol. 2017;17:22.
Cornu JN, Gacci M, Hashim H, Herrmann TRW, Malde S, Netsch C, et al. EAU guidelines on non-neurogenic male lower urinary tract symptoms (LUTS). 2024;67:1099–109.
Gacci M, Sebastianelli A, Spatafora P, Corona G, Serni S, De Ridder D, et al. Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base. Ther Adv Urol. 2018;10:79–92.
Gandhi J, Weissbart SJ, Smith NL, Kaplan SA, Dagur G, Zumbo A, et al. The impact and management of sexual dysfunction secondary to pharmacological therapy of benign prostatic hyperplasia. Transl Androl Urol. 2017;6:295–304.
La Vignera S, Aversa A, Cannarella R, Condorelli RA, Duca Y, Russo GI, et al. Pharmacological treatment of lower urinary tract symptoms in benign prostatic hyperplasia: consequences on sexual function and possible endocrine effects. Expert Opin Pharmacother. 2021;22:179–89.
Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat SF, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med. 2014;11:1554–66.
Ottaiano N, Shelton T, Sanekommu G, Benson CR. Surgical complications in the management of benign prostatic hyperplasia treatment. Curr Urol Rep. 2022;23:83–92.
Porto JG, Arbelaez MCS, Blachman-Braun R, Bhatia A, Bhatia S, Satyanarayana R, et al. Complications associated with minimally invasive surgical therapies (MIST) for surgical management of benign prostatic hyperplasia: a Manufacturer and User Facility Device Experience (MAUDE) database review. World J Urol. 2023;41:1975–82.
Cornu JN, Zantek P, Burtt G, Martin C, Martin A, Springate C, et al. Minimally invasive treatments for benign prostatic obstruction: a systematic review and network meta-analysis. Eur Urol. 2023;83:534–47.
Gemma L, Pecoraro A, Sebastianelli A, Spatafora P, Sessa F, Nicoletti R, et al. Impact of minimally invasive surgical procedures for Male Lower Urinary Tract Symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review. Prostate Cancer Prostatic Dis. 2024;27:404–21.
Busetto GM, Lombardo R, De Nunzio C, Santoro G, Tocci E, Schiavone N, et al. Ejaculation sparing of classic and minimally invasive surgical treatments of LUTS/BPH. Prostate Cancer Prostatic Dis. 2025;28:37–44.
Elterman DS, Zorn KC, Chughtai B, Bhojani N. Is it time to offer True Minimally Invasive Treatments (TMIST) for BPH? - A review of office-based therapies and introduction of a new technology category. Can J Urol. 2021;28:10580–3.
Checcucci E, Veccia A, De Cillis S, Piramide F, Volpi G, Amparore D, et al. New ultra-minimally invasive surgical treatment for benign prostatic hyperplasia: a systematic review and analysis of comparative outcomes. Eur Urol Open Sci. 2021;33:28–41.
Sessa F, Bisegna C, Polverino P, Gacci M, Siena G, Cocci A, et al. Transperineal laser ablation of the prostate (TPLA) for selected patients with lower urinary tract symptoms due to benign prostatic obstruction: a step-by-step guide. Urol Video J 2022;15:100167.
Sessa F, Polverino P, Siena G, Bisegna C, Lo Re M, Spatafora P, et al. Transperineal laser ablation of the prostate (TPLA) for lower urinary tract symptoms due to benign prostatic obstruction. J Clin Med. 2023;12:793.
Tzelves L, Nagasubramanian S, Pinitas A, Juliebø-Jones P, Madaan S, Sienna G, et al. Transperineal laser ablation as a new minimally invasive surgical therapy for benign prostatic hyperplasia: a systematic review of existing literature. Ther Adv Urol. 2023;15:17562872231198634.
Tafuri A, Panunzio A, De Carlo F, Luperto E, Di Cosmo F, Cavaliere A, et al. Transperineal laser ablation for benign prostatic enlargement: a systematic review and pooled analysis of pilot studies. J Clin Med. 2023;12:1860.
Knoll T, Omar MI, Maclennan S, Hernández V, Canfield S, Yuan Y, et al. Key steps in conducting systematic reviews for underpinning clinical practice guidelines: methodology of the European Association of Urology. Eur Urol. 2018;73:290–300.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355:i4919.
Cai HJ, Fang JH, Kong FL, Xu CK, Chen CH, Wang W, et al. Ultrasound-guided transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a new minimally invasive interventional therapy. Acta radiol. 2022;63:553–8.
Patelli G, Ranieri A, Paganelli A, Mauri G, Pacella CM. Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Cardiovasc Intervent Radiol. 2017;40:1440–6.
Pacella CM, Patelli G, Iapicca G, Manenti G, Perretta T, Ryan CP, et al. Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Prostate Cancer Prostatic Dis. 2020;23:356–63.
de Rienzo G, Lorusso A, Minafra P, Zingarelli M, Papapicco G, Lucarelli G, et al. Transperineal interstitial laser ablation of the prostate, a novel option for minimally invasive treatment of benign prostatic obstruction. Eur Urol. 2021;80:95–103.
Frego N, Saita A, Casale P, Diana P, Contieri R, Avolio PP, et al. Feasibility, safety, and efficacy of ultrasound-guided transperineal laser ablation for the treatment of benign prostatic hyperplasia: a single institutional experience. World J Urol. 2021;39:3867–73.
Manenti G, Perretta T, Calcagni A, Ferrari D, Ryan CP, Fraioli F, et al. 3-T MRI and clinical validation of ultrasound-guided transperineal laser ablation of benign prostatic hyperplasia. Eur Radiol Exp. 2021;5:41.
Polverino P, Lore M, Saladino M, Pecoraro A, Moscardi L, Rivetti A, et al. Could transperineal interstitial laser ablation of the prostate be the right option for highly comorbid patients with lower urinary tract symptoms due to benign prostatic obstruction? A preliminary single-center experience focusing on functional and safety outcomes. Minerva Urol Nephrol. 2023;76:646–9.
Bertolo R, Iacovelli V, Cipriani C, Carilli M, Vittori M, Antonucci M, et al. Ejaculatory function following transperineal laser ablation vs <scp>TURP < /scp> for benign prostatic obstruction: a randomized trial. BJU Int. 2023;132:100–8.
Canat HL, Gurbuz C, Bozkurt M. Transurethral resection of the prostate (TURP) versus transperineal laser ablation (TPLA) due to benign prostatic hyperplasia (BPH): prospective and comparative study. Int Urol Nephrol. 2023;55:2747–52.
Destefanis P, Sibona M, Vitiello F, Vercelli E, Micai L, Montefusco G, et al. Trans - Perineal laser ablation of the prostate in high surgical risk patients affected by severe lower urinary tract symptoms related to benign prostatic obstruction. Prostate Cancer Prostatic Dis. 2023;27:693–9.
Laganà A, Di Lascio G, Di Blasi A, Licari LC, Tufano A, Flammia RS, et al. Ultrasound-guided SoracteLiteTM transperineal laser ablation (TPLA) of the prostate for the treatment of symptomatic benign prostatic hyperplasia (BPH): a prospective single-center experience. World J Urol. 2023;41:1157–62.
Minafra P, Derienzo G, Gerbasi S, Cindolo L, Battaglia M, Ditonno P. Three years outcomes of transperineal laser ablation of the prostate. Minerva Urol Nephrol. 2023;75:471–8.
Patelli G, Altieri VM, Ierardi AM, Carnevale A, Chizzoli E, Baronchelli F, et al. Transperineal laser ablation of the prostate for symptomatic benign prostatic hyperplasia: long-term follow-up in 40 patients. J Vas Interv Radiol. 2024;35:1187–93.
van Kollenburg R, van Riel L, Bloemen P, de Reijke T, Beerlage H, de Bruin D, et al. Transperineal laser ablation as treatment for benign prostatic obstruction: safety, feasibility and functional outcomes—A pilot study. BJUI Compass. 2024;5:52–9.
Lo Re M, Polverino P, Rivetti A, Pecoraro A, Saladino M, Pezzoli M, et al. Transperineal laser ablation (TPLA) of the prostate for benign prostatic obstruction: the first 100 patients cohort of a prospective, single-center study. World J Urol. 2024;42:402.
Bianco FJ, Luna E, Lopez-Prieto A, González P, Gheiler EL, Kaufman AM, et al. Office-based transperineal laser ablation for benign prostatic hyperplasia under local anesthesia: 2-year results from a dose range confirmatory trial. JU Open Plus. 2024;2:e00008.
Cai H, Zhu C, Fang J. Ultrasound-guided perineal laser ablation versus prostatic arterial embolization for benign prostatic hyperplasia: two similar short-term efficacies. Acta radiol. 2023;64:2033–9.
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The clavien-dindo classification of surgical complications. Ann Surg. 2009;250:187–96.
Baerlocher MO, Nikolic B, Sze DY. Adverse event classification: clarification and validation of the society of interventional radiology specialty–specific system. J Vas Interv Radiol. 2023;34:1–3.
Cocci A, Pezzoli M, Bianco F, Blefari F, Bove P, Cornud F, et al. Transperineal laser ablation of the prostate as a treatment for benign prostatic hyperplasia and prostate cancer: the results of a Delphi consensus project. Asian J Urol. 2024;11:271–9.
Cornu JN, Ahyai S, Bachmann A, de la Rosette J, Gilling P, Gratzke C, et al. A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update. Eur Urol. 2015;67:1066–96.
Lambertini L, Sandulli A, Coco S, Paganelli D, Cadenar A, Dell’Oglio P, et al. Complication rate across the minimally invasive surgical treatments (MISTs): where do we stand? A systematic review of the literature. Prostate Cancer Prostatic Dis. 2024 Oct 22. https://doi.org/10.1038/s41391-024-00900-5. Epub ahead of print. PMID: 39438691.